US equities
|
MU
$885.08
▼-4.96%
TSLA
$350.63
▼-3.26%
NVDA
$213.68
▼-1.64%
AAPL
$340.91
▼-0.32%
SPCX
$143.62
▼-3.36%
META
$706.12
▼-4.15%
SNDK
$1,311.37
▼-5.98%
MSFT
$525.94
▼-2.50%
MU
$885.08
▼-4.96%
TSLA
$350.63
▼-3.26%
NVDA
$213.68
▼-1.64%
AAPL
$340.91
▼-0.32%
SPCX
$143.62
▼-3.36%
META
$706.12
▼-4.15%
SNDK
$1,311.37
▼-5.98%
MSFT
$525.94
▼-2.50%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
35.95
-1.77 (-4.69%)
Delayed Quote
Updated: 2:58 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nektar Therapeutics - Common Stock
< Previous
1
2
3
Next >
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
May 05, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
May 04, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
May 04, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
May 04, 2026
From
Schall Law
Via
GlobeNewswire
NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
April 30, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 30, 2026
From
Schall Law
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
April 30, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 28, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
April 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
April 27, 2026
From
Rosen Law Firm
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 27, 2026
From
Schall Law
Via
GlobeNewswire
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
April 23, 2026
From
Robbins LLP
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 23, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
April 23, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
April 21, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 21, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 20, 2026
From
Schall Law
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 16, 2026
From
Schall Law
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 14, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 13, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
April 09, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 09, 2026
From
Schall Law
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
April 09, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 07, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 03, 2026
From
Schall Law
Via
GlobeNewswire
< Previous
1
2
3
Next >
